---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-014944"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:36:01.486466+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MiNK Therapeutics issues up to $5.0M convertible promissory note to Agenus at 2% interest

## Summary
- Principal amount up to $5.0M; interest rate 2% per annum, accruing but payable upon conversion or maturity.
- Demand repayment on or after Jan 1, 2026; optional conversion into equity upon qualified financing at Agenus's election.
- Funds may be drawn in increments with Agenus's consent; advances may include payments made by Agenus on Company's behalf.

## SEC filing metadata
- accession: 0000950170-24-014944
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000095017024014944/0000950170-24-014944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000095017024014944/inkt-20240212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-014944
- JSON: https://secwatch.observer/filing/0000950170-24-014944.json
- Plain text: https://secwatch.observer/filing/0000950170-24-014944.txt

## Key facts
- Debt Financings
  MiNK Therapeutics, Inc. incurred convertible notes of up to $5.0 million with Agenus Inc. at 2% maturing on or after January 1, 2026.
  - Instrument: convertible notes
  - Principal: up to $5.0 million
  - Counterparty: Agenus Inc.
  - Rate: 2%
  - Maturity: on or after January 1, 2026
  - Event: incurrence
  source text: On February 12, 2024, MiNK Therapeutics, Inc. (the “Company”) and Agenus Inc. (“Agenus”) entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $5.0 million (the “Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840229/000095017024014944/0000950170-24-014944-index.htm
- Material Agreements
  MiNK Therapeutics, Inc. entered into Convertible Promissory Note Purchase Agreement with Agenus Inc. valued at $5.0 million (effective 2024-02-12).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: Agenus Inc.
  - Value: $5.0 million
  - Effective: 2024-02-12
  source text: On February 12, 2024, MiNK Therapeutics, Inc. (the “Company”) and Agenus Inc. (“Agenus”) entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $5.0 million (the “Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840229/000095017024014944/0000950170-24-014944-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.